Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01CA284646 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
| Kaiser Permanente | OTHER |
Not provided
Not provided
Not provided
Not provided
This observational study evaluates the effectiveness of computed tomography (CT) imaging surveillance after curative-intent treatment for stage I-IIIA non-small cell lung cancer (NSCLC) in a diverse U.S. population.
The main questions are:
How do CT surveillance use and adherence vary by race, ethnicity, and socioeconomic status?
Does semi-annual CT surveillance improve outcomes compared with annual surveillance?
Adults ages 20-90 with stage I-IIIA NSCLC treated between 2012 and 2026 will be identified using OneFlorida+ electronic health records, tumor registry data, claims, and clinical notes. Patients will be followed for up to five years after curative-intent therapy to evaluate surveillance patterns, recurrence, second primary lung cancers, complications, and survival.
This study, Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations (PLuS2), is an observational cohort study designed to evaluate real-world computed tomography (CT) imaging surveillance strategies following curative-intent treatment for early-stage non-small cell lung cancer (NSCLC). The study uses existing clinical data and does not assign interventions.
The study population includes adults ages 20-90 with pathologically confirmed stage I-IIIA NSCLC who completed curative-intent therapy. Patients treated between 2012 and 2026 will be identified within the OneFlorida+ Clinical Research Consortium and followed for up to five years after treatment to assess surveillance patterns and outcomes.
UF Health serves as the data coordinating site in collaboration with the OneFlorida+ Data Trust. Data sources include structured electronic health records, tumor registry data, selected claims, and unstructured clinical notes. Data extraction and cohort identification are conducted centrally using standardized definitions aligned with the PCORnet Common Data Model.
The primary objectives of the study are to:
Clinical natural language processing (NLP) methods are used to classify CT scans as routine surveillance versus symptom-directed diagnostic imaging and to extract recurrence indicators, smoking history, and selected social determinants of health from unstructured clinical notes. NLP outputs are integrated with structured data to improve classification accuracy and completeness.
Quality assurance procedures include automated checks for completeness, range, and internal consistency, validation against source EHR and tumor registry records, and maintenance of a standardized data dictionary defining all variables and coding systems. Standard operating procedures govern cohort assembly, quarterly data refreshes, data management, analysis, and reporting.
The expected cohort size is approximately 1,700 patients, providing sufficient power to evaluate surveillance utilization patterns and outcome differences by surveillance interval. Missing data will be addressed using multiple imputation and sensitivity analyses.
Statistical analyses include descriptive methods, multivariable and mixed-effects regression models, and time-to-event and competing-risk analyses. Results from the observational analyses will be used as inputs for microsimulation modeling to estimate long-term population-level outcomes associated with different CT surveillance strategies.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Target population includes confirmed stage I-IIIA NSCLC patients within the OneFlorida+ Consortium |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Guideline Adherence to Chest CT Surveillance | Proportion of patients who complete guideline-recommended post-treatment chest CT surveillance within prespecified rolling surveillance windows. Guideline adherence will be defined using ±1-month and ±2-month allowable windows around each recommended surveillance time point. Semi-annual surveillance (Years 0-2) will be assessed at recommended months 6, 12, 18, and 24, with adherence defined as completing a CT within months 5-7 or 4-8, 11-13 or 10-14, 17-19 or 16-20, and 23-25 or 22-26, respectively. Annual surveillance (Years 3-5) will be assessed at recommended months 36, 48, and 60, with adherence defined as completing a CT within months 35-37 or 34-38, 47-49 or 46-50, and 59-61 or 58-62, respectively. Patients will be censored at recurrence, death, loss to follow-up, or end of study. | Up to 5 years after treatment completion |
| Annual Rates of Guideline-Concordant Surveillance CT Imaging during post-treatment Years 1-5. | Surveillance begins at completion of curative-intent therapy (surgery or SBRT ± adjuvant therapy), and only routine surveillance scans are included. In Years 1-2, surveillance is guideline-concordant if CTs are completed within rolling 4-8-month intervals following either treatment completion or the prior surveillance CT. In Years 3-5, surveillance is guideline-concordant if CTs occur within rolling 10-14-month intervals from the prior CT. Patients are censored at recurrence, death, loss to follow-up, or end of study period. | Year-specific rates are assessed annually for up to 5 years post-treatment. |
| Time to First Recurrence | Time from completion of curative-intent therapy to the first documented cancer recurrence (local, regional, or distant). Recurrence will be identified using structured electronic health records (EHR) recurrence fields, validated recurrence-detection algorithms, cancer registry linkage, and natural language processing (NLP) based extraction from radiology reports and clinical notes. Patients will be censored at death without recurrence, loss to follow-up, or completion of 5-year follow-up. | Up to 5 years post-treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| CT Surveillance Pattern Classification (0-5 Years) | Patients will be categorized into one of four mutually exclusive surveillance patterns based on completed post-treatment surveillance CT imaging from 0-5 years following curative intent therapy:
|
| Measure | Description | Time Frame |
|---|---|---|
| Model Projected Recurrence/SPLC Detection Timing and Mode | Model estimated timing of recurrence and SPLC detectability and symptom onset, and projected proportion detected through surveillance imaging versus symptom-prompted evaluation under alternative surveillance strategies. Measure Description: Projected distributions of:
|
Inclusion Criteria:
Surgical resection, or Stereotactic body radiation therapy (SBRT), with or without adjuvant therapy.
Structured EHR data (including tumor registry linkage, imaging, procedures, and vital statistics), and Unstructured clinical documents (clinic notes, radiology reports, pathology reports) enable NLP extraction.
- Have ≥1 follow-up encounter in the EHR after treatment completion to allow surveillance assessment.
Exclusion Criteria:
Small-cell lung cancer Carcinoid tumors Rare non-NSCLC primary tumors
No post-treatment clinical notes No radiology/pathology records No linked tumor registry or vital status data
Not provided
Not provided
Not provided
Not provided
The study population includes adults diagnosed with primary, pathologically confirmed stage I-IIIA non-small cell lung cancer (NSCLC) who received curative intent therapy (surgery or SBRT ± adjuvant therapy) within the UF Health system and are captured in the OneFlorida+ data network. Eligible patients must have completed treatment and survived ≥5 months to allow surveillance assessment. Structured EHR, tumor registry data, and unstructured clinical documentation will be used, with NLP applied to classify surveillance vs. symptom-directed imaging and extract clinical, functional, and social determinants of health.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Florida College of Medicine | Gainesville | Florida | 32610 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| D002289 | Carcinoma, Non-Small-Cell Lung |
| D004194 | Disease |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Time to Second Primary Lung Cancer (SPLC) |
Time from completion of curative-intent therapy to diagnosis of a metachronous second primary lung cancer (SPLC). SPLC will be defined using standard criteria, including AJCC TNM staging, histologic distinction from the index tumor, cancer registry confirmation, and pathology report verification. Among patients who develop SPLC, we will evaluate stage at SPLC diagnosis, histologic subtype (including bronchioloalveolar carcinoma), and receipt of adjuvant therapy. Patients will be censored at death without SPLC, recurrence without SPLC, or completion of follow-up. This outcome will be analyzed as a time-to-event measure consistent with other survival endpoints. |
| Up to 5 years or end of follow up |
| All-cause mortality | Time from completion of curative intent treatment to death from any cause. Vital status will be ascertained through institutional cancer registries, the National Death Index, and state death certificate data. | Up to 5 years post-treatment (or longest available follow-up). |
| Lung Cancer-Specific Mortality | Time from completion of curative-intent treatment to death attributed specifically to lung cancer, analyzed under a competing-risk framework in which non-lung cancer deaths are treated as competing events. Cause of death will be determined using institutional cancer registry data and National Death Index linkage. | Up to 5 years following treatment completion. |
| Mode of Recurrence Detection | Classification of recurrence mode at the time of first recurrence. Recurrences will be categorized as:
Detection mode will be determined using electronic health record (EHR) documentation and natural language processing (NLP) extraction from radiology reports and clinical notes. Timing of recurrence (time to event) will be evaluated separately; early vs. later surveillance detection will be described, but has no clinical implications if timing windows shift. | Assessed at the time of recurrence, up to 5 years following treatment completion. |
| Type of SPLC Detection | Classification of metachronous second primary lung cancer (SPLC) as either: Surveillance-detected: Identified during routine surveillance CT imaging in asymptomatic patients. Symptom-detected: Identified after new or worsening symptoms prompted diagnostic evaluation. Detection mode will be determined using EHR documentation and NLP extraction from radiology reports and clinical notes. | At SPLC diagnosis (≤5 years following treatment completion). |
| Model-Projected Long-Term Survival Under Alternative Surveillance Strategies | Microsimulation-projected overall and lung cancer-specific survival under semi-annual versus annual CT surveillance schedules. The model will be calibrated using recurrence, SPLC, and mortality data from Aims 1-2 and extrapolated to national incidence patterns using SEER data. Measure Description: Difference in projected survival outcomes between semi-annual and annual surveillance strategies, reported as:
Model estimates will be derived from a calibrated Markov microsimulation model informed by Aims 1-2 and extrapolated using SEER incidence. | At 5 years, 10 years, and over the model-projected lifetime horizon after the index surveillance decision |
| 0-5 years post treatment |
| CT Surveillance Utilization Rate | Intensity of surveillance CT use, measured as scans per person time and/or completion of guideline-recommended surveillance intervals | Up to 5 years post treatment |
| False Positive Surveillance CT Results | Surveillance CT scans that trigger additional diagnostic evaluation (biopsy, PET CT, or repeat imaging) without a lung cancer diagnosis (recurrence or SPLC) within 6 months of the index scan. Results will be classified as true positive, false positive, true negative, or false negative using cancer registry data and EHR documentation | Up to 5 years |
| Downstream Diagnostic Procedures After Surveillance CT | Frequency and type of diagnostic procedures, both invasive and non-invasive, performed following surveillance CT imaging, including transthoracic biopsy, transbronchial biopsy, bronchoscopy, and PET-CT. | Up to 5 years following treatment completion |
| Procedure Related Complications | Complications occurring within 7 days and 30 days of invasive diagnostic procedures (transthoracic, transbronchial, or surgical biopsies), including:
| Up to 5 years following treatment completion |
| Recurrence Site / Pattern (Registry Based) | Classification of recurrence site as local, regional, or distant, based on cancer registry definitions. | At recurrence (≤5 years) |
| Receipt of Treatment Following Recurrence or SPLC | Time to treatment initiation following recurrence or SPLC diagnosis, and classification of treatment modality, including surgery, SBRT, targeted therapy, and immune checkpoint inhibitor therapy. | At recurrence or SPLC diagnosis (≤5 years) |
| From the index surveillance decision through the model-projected lifetime horizon (5 years, 10 years) |
| Model Projected Population Impact Under Varying Surveillance Uptake | Sensitivity analyses evaluating population-level outcomes under varying surveillance uptake levels (e.g., 50%, 70%, 90% adherence), including projected lung cancer deaths averted, earlier detection, false positive CTs, and downstream diagnostic complications. Measure Description: Projected population impacts under alternative surveillance schedules and uptake levels, including:
| Over the model-projected lifetime horizon after the index surveillance decision (5 years, 10 years) |
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |